Additionally, the combined use of PI3K/mTOR inhibitors and imatinib demonstrated a synergistic inhibition of the malignant behavior of GIST.[20] In estrogen receptor (ER)‐positive breast cancer, Turrell et al. Here, MTOR is linked to gastrointestinal stromal tumor.